International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 074-079
COMPARISON OF THE TWO TREATMENTS FOR PATIENTS WITH METASTATIC PROSTATE CANCER: LEUPROLIDE ACETATE AND FLUTAMIDE VS BILATERAL ORCHIECTOMY AND FLUTAMID
M. ABDURRAHİM İMAMOĞLU1, ORHAN YİĞİTBAŞI1, UFUK ÖZTÜRK1, CAN TUYGUN1, M. NURETTİN SERTÇELİK1
SSK Ankara Eğitim Hastanesi 1. Üroloji Kliniği, Ankara
Keywords: metastatic prostate cancer, orchiectomy, leuprolide asetate, flutamide
Fifty three patients with metastatic prostate cancer who did not receive treatment before were seperated into two groups. Twenty-eight of them were given leuprolid and flutamid and 25 of them underwent bilateral orchiectomy and maximal androgen blockage with flutamide. Patients were evaluated seperately in terms of survival and progression time and adverse effects in both groups. In leuprolide and flutamide group, mean progression time was found 14.2 months and mean survival time was 26.5 months. These values were 17.5 months and 28.2 months accordingly in the group with orchiectomy and flutamide. Toxicity was feasible in both treatment groups. Patient's age, social status and cost-effectiveness must be considered when taking a desicion about the kind of the treatment for patients with metastatic prostate cancer.
M. ABDURRAHİM İMAMOĞLU1, ORHAN YİĞİTBAŞI1, UFUK ÖZTÜRK1, CAN TUYGUN1, M. NURETTİN SERTÇELİK1
SSK Ankara Eğitim Hastanesi 1. Üroloji Kliniği, Ankara
Keywords: metastatic prostate cancer, orchiectomy, leuprolide asetate, flutamide
Fifty three patients with metastatic prostate cancer who did not receive treatment before were seperated into two groups. Twenty-eight of them were given leuprolid and flutamid and 25 of them underwent bilateral orchiectomy and maximal androgen blockage with flutamide. Patients were evaluated seperately in terms of survival and progression time and adverse effects in both groups. In leuprolide and flutamide group, mean progression time was found 14.2 months and mean survival time was 26.5 months. These values were 17.5 months and 28.2 months accordingly in the group with orchiectomy and flutamide. Toxicity was feasible in both treatment groups. Patient's age, social status and cost-effectiveness must be considered when taking a desicion about the kind of the treatment for patients with metastatic prostate cancer.